Hepatitis G Virus

Updated: 2026-09-20

Overview

Hepatitis G Virus (HGV), also known as GB virus C, was discovered in 1995 during studies of hepatitis cases. Despite its name, HGV is not a primary cause of hepatitis and is classified as an 'orphan virus' due to its uncertain disease association. It shares genomic similarities with hepatitis C virus but replicates in lymphocytes rather than hepatocytes. HGV is globally distributed, with prevalence rates varying by region (1–5% in blood donors). Vertical and sexual transmission routes are documented, though parenteral exposure remains the primary mode. Persistent infection occurs in 10–20% of cases, but most infections resolve spontaneously without treatment.

Key Features

HGV is characterized by its high genetic variability, with six major genotypes showing geographic patterns (e.g., genotype 1 in West Africa, genotype 3 in Asia). The virus lacks a robust envelope protein, contributing to its low immunogenicity and difficulty in serological detection. Notably, some studies suggest HGV may modulate HIV progression by downregulating host chemokine receptors. However, its clinical significance remains debated, and routine testing is not recommended outside research settings. Viral load assays and PCR-based methods are the gold standards for detection.

Application Areas

In biomedical research, HGV serves as a model for studying RNA virus evolution and host immune evasion. Its interaction with HIV has spurred investigations into potential therapeutic applications, though no commercial products exist. Diagnostically, HGV testing is primarily used in blood safety programs (e.g., in Japan) and epidemiological studies. Research-grade reagents include PCR primers, recombinant antigens, and monoclonal antibodies. Industrial buyers should validate analytical sensitivity (≥95% for genotype inclusivity) when selecting assay kits.

Precautions

Laboratories handling HGV specimens must adhere to biosafety Level 2 (BSL-2) standards, including PPE and waste decontamination procedures. False-negative results may occur with certain genotypes, necessitating multi-region amplification protocols. For procurement, ensure suppliers provide complete genomic sequence data and performance characteristics (e.g., limit of detection ≤50 IU/mL). Transport specimens at -70°C for long-term storage, avoiding repeated freeze-thaw cycles that degrade viral RNA.

B2B Procurement Guide

Commercial HGV products fall into three categories: (1) Nucleic acid testing kits (e.g., real-time PCR), (2) Recombinant proteins for antibody detection, and (3) Control panels for assay validation. Leading manufacturers include Roche Molecular Systems and Siemens Healthineers. Bulk buyers should request Certificate of Analysis (CoA) documents detailing lot-specific sensitivity data. For research institutions, consider modular purchasing—core reagents with optional genotype-specific add-ons. MOQs typically start at 50 tests for kits, with 4–6 week lead times for custom orders.